Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Management of Bleeding in Patients Taking Oral Anticoagulants
JAMA 319:2032-2033, Anderson, I.,et al, 2018
Andexxa-An Antidote for Apixaban and Rivaroxaban
JAMA 320:399-400, , 2018
Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Stroke 48:1432-1437, Steiner, T.,et al, 2017
Early Clinical and Radiological Course, Management, and Outcome of Intracerebral Hemorrhage Related to New Oral Anticoagulants
JAMA Neurol 73:169-177,155, Purrucker, J.C.,et al, 2016
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
NEJM 375:1131-1141,1185, Connolly, S.J.,et al, 2016
Anticoagulant Reversal, Blood Pressure Levels, and Anticoagulant Resumption in Patients with Anticoagulation-Related Intracerebral Hemorrhage
JAMA 313:824-836, Kuramatsu, J.B.,et al, 2015
Idarucizumab for Dabigatran Reversal
NEJM 373:511-520, Pollack, C.V.,et al, 2015
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
NEJM 373:2413-2424,2471, Siegal, D.M.,et al, 2015
Using Dabigatran in Patients with Stroke A Practical Guide for Clinicians
Stroke 43:271-279, Alberts, M.J.,et al, 2012
Acutely Injured Patients on Dabigatran
NEJM 365:2039-2040, Cotton, B.A.,et al, 2011
Risk of Thromboembolic Events in Controlled Trials of rFVIIa in Spontaneous Intracerebral Hemorrhage
Stroke 39:850-856, Diringer,M.N.,et al, 2008
Multiple Ischemic Strokes Associated With Use of Recombinant Activated Factor VII
Arch Neurol 64:879-881, Libman,R.B.,et al, 2007
Intracerebral Hemorrhage Associated with Oral Anticoagulant Therapy
Stroke 37:256-262, Steiner, T.,et al, 2006
Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa
JAMA 295:293-298, OConnell,K.A.,et al, 2006
Unexpected Posthemorrhagic Hydrocephalus in Patients Treated with rFVIIa
Neurol 67:1096, Subramaniam,S.,et al, 2006
Myocardial Injury in patients with Intracerebral Hemorrhage Treated with Recombinant Factor VIIa
Neurol 67:1053-1055, Sugg,R.M.,et al, 2006
Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
NEJM 352: 777-785, 828, Mayer, S.A., et al, 2005
Safety of Discontinuation of Anticoagulation in Patients with Intracranial Hemorrhage at High Thromboembolic Risk
Arch Neurol 57:1710-1713,1682, Phan,T.G.,et al, 2000
Oral Anticoagulants and Intracranial Hemorrhage, Facts and Hypotheses
Srroke 26:1471-1477, Hart,R.G.,et al, 1995
A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion
NEJM 394:442-450, Ryan,S.J.,et al, 2026
Restless Legs Syndrome, A Review
JAMA 335:703-714, Winkelmen,J.W. & Wipper, B., 2026
Commonly Used Interventional Procedures for Non-Cancer Chronic Spine Pain: A Clinical Practice Guideline
BMJ 388:e079970, Busse,J.W.,et al, 2025
Severe Myotonic Crisis Resembling Malignant Hyperthermia
Neurol 104:e213497, Wadhwani,A.R.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
A 69-Year-Old Woman with Ophthalmoplegia
Neurol 104:e213763, Yu, H & Frey, J, 2025
Risk of Dementia in Individuals with Emergency Department Visits or Hospitalizations Due to Cannabis
JAMA Neurol 82:570-579, Myran,D.T.,et al, 2025
AAV9-Mediated Gene Therapy for Infantile-Onset Pompes Disease
NEJM 392:2438-2446, 2477, Ma,X.,et al, 2025
Real-World Evidence of Brexpiprazole Use and 6-Month Mortality, Hospitalization, and Emergency Department Visits Among Persons with Dementia
Neurol 105: e213717, Zissimopoulos, J.,et al, 2025
Neuroimaging Findings in Children and Young Adults with Neurotoxicity after CAR T-Cell Therapy for B-Cell Malignancies
Neurol 105:e214086, McGuire,J.L.,et al, 2025
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
Angioedema Following Tenecteplase for Acute Ischemic Stroke
Stroke 55:e242-e244, Dellabella,A.,et al, 2024
Angioedema After Use of Recombinant Tissue-Type Plasminogen Activators in Stroke
Stroke 55:2193-2197, Hutten,E., 2024
Neuroleptic Malignant Syndrome
NEJM 391:1130-1138, Wijdicks,E.F.M. & Ropper,A.H., 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024
Cerebral Venous Thrombosis in a Transgender Man Receiving Testosterone Therapy and Progestin Implant
AIM Clin Cases 4:e240196, Chen,D.R.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Phase 2 Trial of Difelikefalin in Notalgia Paresthetica
NEJM 388:511-517, Kin,B.S.,et al, 2023
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
New-Onset Diplopia and Headache in a Patient with Metastatic Breast Cancer
Neurol 100:927-931, Rizzo,S.A.,et al, 2023
Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
NSAIDS, Hormonal Contraception, and Venous Thromboembolism, A Harmful Drug Interaction That Deserves More Attention
BMJ 382:p1990, Schmidt,M., 2023
Trial of Botulinum Toxin for Isolated or Essential Head Tremor
NEJM 389:1753-1765, Marques,A.,et al, 2023
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023